Daniel Heinrich

Our data on prediction of benefit from Radium-223 in #mCRPC @QubPGJCCR #ProEx published today nature.com/articles/s4141…

HERE IN #APCCC24 🇨🇭 IT'S ALL ABOUT THAT PSMA @APCCC_Lugano @Silke_Gillessen @AOmlin @neerajaiims @ravikanesvaran @scserendipity1 @EfstathiouEleni @nataliagandur @SandhuShahneen @ChrisSweens1 @DrSpratticus @soulehoward1 @nealshore @RobertReiterMD @DRathkopf @ColinCPritchard @piet_ost @WilliamOhMD @ProfJOSullivan @DrPaulNguyen @NDowJames @VedangMurthy @declangmurphy @dmukherji @tompowles1 @brian_rini @mrabti_hind @CaPsurvivorship @DrRanaMcKay @MatikainenMika @quimmateo @LoebStacy @Prof_Nick_James @DrMHofman @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @BraunMDPhD @yekeduz_emre @declangmurphy @GGrisay @fabioturco92

#APCCC24 is on the horizon, launching on April 25th! As a consensus conference, it’s the epicentre for bridging clinical gaps in advanced #prostatecancer care. The world’s experts gather to tackle crucial topics and highlight the evolving dynamics of #PCa treatment. 🌍 With an extensive list of global panel members, #APCCC24 is your gateway to the forefront of oncology. Join us for a HYBRID experience that promises to inspire and inform you. 📢 Act swiftly! Less than a month to go, with special rates available and free online access for participants from lower- and lower-middle-income countries. Don’t miss out on the chance to contribute to the consensus that will drive the future of prostate cancer management. 🔗 Secure your spot, join APCCC 2024 TODAY 👉apccc.org #GlobalOncology #ConsensusConference #OncologyResearch #CountdownToEndCancer #GlobalHealth #MedicalConference #OncologyInnovation @Silke_Gillessen @AOmlin @SandhuShahneen @OncoAlert @ChrisSweens1 @DrSpratticus @soulehoward1 @FacsRaja @ravikanesvaran @AnthonyMJoshua @BarbaraJereczek @Prof_Nick_James @DrMHofman @ProfKHerrmann @JGrummet @Nicola_Fossati @a_fatiregun @stefanofanti4 @EfstathiouEleni @ZilliThomas @neerajaiims @scserendipity1 @nataliagandur @tompowles1 @brian_rini @montypal @soulehoward1 @nealshore @charlesryanmd @RobertReiterMD @DRathkopf @ColinCPritchard @PCaParker @ProfPadhani @piet_ost @WilliamOhMD @ProfJOSullivan @DrPaulNguyen @NDowJames @VedangMurthy @declangmurphy @dmukherji @mrabti_hind @morr316 @CaPsurvivorship @amerseburger @DrRanaMcKay @MatikainenMika @quimmateo @LoebStacy

Four hours with Tom and Brian on my ears and this view in front of my eyes! Really exhausting 😎☀️😁 @tompowles1 @brian_rini @Uromigos

Verdens beste kreftbehandling on tidsskriftet.no tidsskriftet.no/2021/09/leder/… #tidsskriftet via @Tidsskriftet

Lenvatinib + pembro is at least as active as other VEGF/IO combos. RR of 70% + PFS of 24 mnths (yes 24) are eye catching. OS of 0.66 in line with others. Low LFT AEs is important. Lenvatinib + evero has PFS but not OS signal. It’s role requires definition. ?post cabo/nivo #GU21

Overbevist at det å godkjenne COVID-19 vaksinene nå er riktig og glad for at utviklingen har gått så fort! Støtter også veldig å flytte helsepersonell frem i prioriteringskøen og skal utvilsomt være en av de første som vaksineres selv når det er min tur! dagensmedisin.no/artikler/2020/…

SØNDAGSKONK #1: Best siste 6 hull av @McIlroyRory & @JonRahmpga. Retweet for McIlroy, ´like´for Rahm. #ESNgolf @Golfshopen_no

Out now! Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 published on @EUplatinum 👉 europeanurology.com/article/S0302-… #apccc19 #apccc21 #prostatecancer @Els_Urology @urotoday

Getting ready for day 1 #ASCO19

MASTERSKONK LØRDAG: Best siste 9 hull av @TigerWoods & @IanJamesPoulter. Retweet for Tiger, ´like´for Poulter. Poulter-sko i premie! @PerHaugsrud #ESNgolf

MASTERSKONK FREDAG: Best siste 9 hull mellom @TigerWoods & @McIlroyRory. Retweet for Tiger, ´like´for Rory. Lykke til! @PerHaugsrud 👍

Den mest udiskutable fredsprisen på lenge deles ut, men avisene rydder forsidene for Farmen-Kjetil. Det får være måte på forsimpling av offentligheten, @vgnett og @dagbladet. Dette er flaut.

Bent lanserer #ekspertpanelet instagram.com/p/BpmNgwQHXKl/…

Bent lanserer #ekspertpanelet @ Haukeland universitetssjukehus instagram.com/p/BpmM-3iHe11/…

@Prof_Nick_James Thanks for the support! Not everyone agreed.

Heidenrich: ERA223 shows importance of bone health protection in mCRPC. Disagrees with EMA licence change for Ra223 (as do I) #ESMO18

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma | Business Wire businesswire.com/news/home/2018…

Great presentation of our latest #STAMPEDEtrial M1 RT data by @PCaParker Simultaneous publication in @TheLancet Here’s the link dx.doi.org/10.1016/S0140-… #ESMO18

18% had ADT + Doc as their SOC. adding RT to this had a similar HR to the effect of adding RT to ADT monotherapy (slightly bigger in fact). ADT/Doc/RT will be our SOC for this group in future in chemo fit pts